Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Endocrinol.

Title: European journal of endocrinology

Publisher: Bioscientifica

ISSN (Electronic): 1479-683X

ISSN (Print): 0804-4643

Publication date (Electronic): March 2018

Volume: 178

Issue: 3

Affiliations

[1 ] St Vincent's Hospital and Garvan Institute of Medical ResearchSydney, Australia.

[2 ] Department of Internal Medicine (Section Endocrinology) & Clinical EpidemiologyLeiden University Medical Centre, Leiden, The Netherlands.

[3 ] ENDOC Center for Endocrine TumorsHamburg, Germany.

[4 ] University BelgradeBelgrade, Serbia.

[5 ] Centre de Pathologie et de Biologie EstGroupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.

[6 ] Fédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Université de Lyon, Bron, France.

[7 ] Department of EndocrinologySkåne University Hospital Malmö, University of Lund, Lund, Sweden pia.burman@med.lu.se.

Article

Publisher Item ID: EJE-17-0933

DOI: 10.1530/EJE-17-0933

PubMed ID: 29330228

SO-VID: 13b48a41-f4da-42da-b424-115d7ef8b093

History

Data availability:

Comments

Comment on this article

Cited by 104

See all cited by